BIOGNOSYS
21.10.2021 16:02:05 CEST | Business Wire | Press release
Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced they will be presenting major scientific and technological advances on their proprietary proteomics research services, software, and kits at the American Society for Mass Spectrometry (ASMS) Annual Conference from October 31st to November 4th in Philadelphia (USA).
Biognosys will present a record number of 3 oral presentations, 10 scientific posters, 2 poster collaborations, 1 workshop panel, and 2 Spectronaut™ breakfast seminars . In addition, their team of scientific experts will be present at booth #224 to answer questions and demo software. Further demo sessions will be offered at the Bruker Daltonics booth #719.
Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly in the areas of plasma proteomics, immunopeptidomics, and proteomics data analysis.
Lukas Reiter, PhD, Chief Technology Officer of Biognosys:
“Our major contribution to the ASMS scientific program is a testimony of Biognosys’ relentless commitment to innovation in mass spectrometry-based proteomics and progress in life science and clinical research.”
Discovering biomarkers in cancer with next-generation plasma proteomics
The plasma proteome is an underexplored source of insights on the health state of an individual. Biognosys will present results from a deep human plasma profiling study on a cohort of 180 lung, breast, colorectal, pancreatic, and prostate cancer patients, using an early version of their next-generation Plasma Biomarker Discovery workflow, launching in November. The workflow is optimized for use on Thermo Fisher Scientific Exploris 480 and FAIMS Pro instruments. Out of the entire plasma proteome, they quantified over 2,700 proteins and identified a protein panel with a significant positive predictive value for individual cancer stages.
Andreas Huhmer, Senior Director Life Sciences Research OMICS Marketing
at Thermo Fisher Scientific:
“Biognosys has a proven track record for maximizing all innovative features of the Thermo Scientific™ Orbitrap™ mass spectrometers in state-of-the-art proteome analysis. Their new Plasma Biomarker Discovery workflow is a good example of this. The unprecedented depth and quantitative precision they can achieve, coupled with the inherently unbiased nature of mass spectrometry-based analysis, has the potential to take plasma biomarker discovery to the next level.”
Gaining insights on the immune system to support personalized drug development
Immunopeptides play an essential role in the immune system and can be analyzed to support the development of personalized treatments. Mass spectrometry is currently the only technology that can reliably measure and identify immunopeptide profiles of biological samples on a large scale. Biognosys will present their immunopeptidomics workflow, optimized to provide deep and comprehensive biological insights on the immune system in large-scale clinical studies.
Turning data to insights with Spectronaut™, SpectroMine™, and SpectroDive™
Biognosys provides leading software products for proteomics data analysis. In a series of talks, their team will detail how they leverage the latest developments in Machine Learning and Deep Learning to allow deeper insights into the proteome. Biognosys is also excited to host two breakfast seminars with three guest speakers sharing their latest results from using Spectronaut in their research projects. In addition, a sneak-peak into the next planned release will be disclosed.
Gary Kruppa, Vice President, Proteomics at Bruker Daltonics:
“Biognosys’ software tools are among the top solutions for the analysis of proteomics data generated with Bruker instruments. Particularly the latest Spectronaut version yields spectacular performance improvements for dia-PASEF data. We invite all Bruker users to experience Spectronaut’s capabilities and enjoy the exceptional support Biognosys provides.”
Visit biognosys.com/asms2021 for a complete overview of Biognosys’ presence at ASMS.
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005530/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International and HSBC Expand Real-Time Treasury Management Services to the Middle East6.10.2026 08:30:00 CEST | Press release
Collaboration extends Ant International’s use of tokenised deposits in UAE, supporting faster treasury transactions Ant International today announced an expanded collaboration with HSBC to enhance real-time treasury management services in the Middle East. By leveraging HSBC’s global Tokenised Deposit Service (TDS), Ant International aims to improve the efficiency of its treasury operations across the region. As part of the collaboration, Ant International has successfully completed pilot transactions across two payment corridors connecting the United Arab Emirates and Hong Kong: Intra-UAE dirham transfers: Real-time, dirham-denominated tokenised deposit transactions within the UAE. Cross-border US dollar payments initiated from the UAE: US dollar-denominated tokenised deposit transfers between the UAE and international markets, including Hong Kong and Singapore. These transactions were initiated via WhaleRTP – Ant International’s proprietary, blockchain-based real-time treasury managem
RoslinCT Awarded £7.25 million Scottish Enterprise R&D Grant to Advance Digital Cell Therapy Manufacturing6.10.2026 08:00:00 CEST | Press release
RoslinCT, a leading global cell therapy Contract Development and Manufacturing Organization (CDMO), today announced it has been awarded a Research & Development grant from Scottish Enterprise to accelerate the digital transformation of its manufacturing operations in Scotland. The funding, supported by a Scottish Enterprise R&D grant of up to £7.25 million, forms part of RoslinCT's ambitious digital expansion plan, a multi-year initiative designed to enhance the company's integrated digital and AI capabilities and further strengthen Scotland's position as a global hub for advanced cell and gene therapy manufacturing. The programme will enable the development of a digitally integrated manufacturing environment, improving operational efficiency, data connectivity and manufacturing excellence across RoslinCT's operations. By creating a more connected and data-driven manufacturing environment, RoslinCT will be better positioned to support clients throughout the product lifecycle, helping b
30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation6.10.2026 07:00:00 CEST | Press release
Galderma celebrates the 30th anniversary of Restylane, its pioneering range of hyaluronic acid (HA) injectables that established the category as the first to market1 With three decades of innovation across technology, packaging, and treatment areas, Restylane continues to meet growing aesthetic needs, including emerging areas such as medication-driven weight loss, skin quality and menopause1-11 This year’s milestones include the approvals of Restylane Shaype™ in the European Union (EU) for enhancement of the chin region, the new state-of-the-art Restylane syringe in the EU, United States (U.S.), and Canada, and Restylane Volyme™* in the U.S. for temple hollowing, with a dual-layer patent-pending technique leveraging both needle and cannula12-18 With more than 80 clinical trials, 180 publications, around 407,000 patients evaluated for safety, and 77 million treatments administered worldwide, Restylane remains a pioneer in science-backed aesthetic innovation and continues to shape the fu
Posiflex Unveils AI-Powered SCO Series Kiosk to Accelerate the Future of Self-Service Retail6.10.2026 04:33:00 CEST | Press release
A modular, smarter self-checkout platform engineered for weighing, RFID, and loss-prevention automation across diverse retail environments Posiflex Technology, Inc., a global leader in Point of Sale (POS) systems and Online-to-Offline (O2O) solutions, proudly introduces the SCO Series Self-Service Kiosks, an AI-powered platform designed to redefine self-service retail by offering flexible system configurations that support either precise weighing-scale transactions or RFID-enabled automated checkout. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261004628458/en/ Posiflex Unveils AI-Powered SCO Series Kiosk to Accelerate the Future of Self-Service Retail Built to address the evolving needs of both traditional fresh-goods environments and modern RFID-driven retail concepts, the SCO Series enables retailers to elevate operational accuracy, accelerate checkout processes, and future-proof store deployments through modular archit
Cities Integrating AI Into Public Services With No Common Framework for Assessing Readiness, Oxford Insights Finds6.10.2026 04:00:00 CEST | Press release
Organisation behind the Government AI Readiness Index proposes a City AI Readiness Index, based on a new study of Abu Dhabi Cities are integrating artificial intelligence into public services and operations with no shared framework for measuring or comparing how prepared they are to do so safely, effectively or accountably. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005281462/en/ Cover of Oxford Insights' latest report on City AI Readiness. (Graphic: AETOSWire) Existing global indices compare countries on legislation, investment and research output, but the AI efforts happening at city level – the level of government where the technology most directly shapes daily life – are not systematically captured. To start closing that gap, Oxford Insights researchers studied AI readiness across six cities. They found that all share the same core priorities, from governance and funding to talent and infrastructure, but take dist
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom